Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 443

1.

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP.

Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652.

PMID:
29846250
2.

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.

Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ.

Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10.

3.

Immune checkpoint pathways in non-small cell lung cancer.

Chae YK, Arya A, Iams W, Cruz M, Mohindra N, Villaflor V, Giles FJ.

Ann Transl Med. 2018 Mar;6(5):88. doi: 10.21037/atm.2017.09.30. Review.

4.

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.

Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20.

PMID:
29559559
5.

Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma.

Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH.

Oncotarget. 2017 Dec 15;9(8):7949-7960. doi: 10.18632/oncotarget.23742. eCollection 2018 Jan 30.

6.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Deng W, Krunic N, Bédoucha V, Gopalakrishna P, Hochhaus A.

J Cancer Res Clin Oncol. 2018 May;144(5):945-954. doi: 10.1007/s00432-018-2604-x. Epub 2018 Feb 22.

7.

Role of artificial intelligence in the care of patients with nonsmall cell lung cancer.

Rabbani M, Kanevsky J, Kafi K, Chandelier F, Giles FJ.

Eur J Clin Invest. 2018 Apr;48(4). doi: 10.1111/eci.12901. Epub 2018 Feb 19. Review.

PMID:
29405289
8.

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.

Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ.

Oncotarget. 2017 Nov 11;8(70):114924-114934. doi: 10.18632/oncotarget.22414. eCollection 2017 Dec 29.

9.

Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.

Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT, Cruz M, Matsangou M, Giles FJ.

Sci Rep. 2018 Jan 18;8(1):1023. doi: 10.1038/s41598-018-19454-3.

10.

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM.

Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21.

PMID:
29275833
11.

Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.

Chae YK, Oh MS, Giles FJ.

Oncologist. 2018 Apr;23(4):410-421. doi: 10.1634/theoncologist.2017-0354. Epub 2017 Dec 14. Review.

PMID:
29242279
12.

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R.

Clin Cancer Res. 2018 Apr 15;24(8):1785-1794. doi: 10.1158/1078-0432.CCR-17-1970. Epub 2017 Dec 6. Review.

PMID:
29212781
13.

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.

PMID:
29203694
14.

Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer.

Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ.

J Gastrointest Oncol. 2017 Oct;8(5):858-866. doi: 10.21037/jgo.2017.06.20.

15.

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.

Mota JM, Collier KA, Barros Costa RL, Taxter T, Kalyan A, Leite CA, Chae YK, Giles FJ, Carneiro BA.

Oncotarget. 2017 Jun 13;8(51):89284-89306. doi: 10.18632/oncotarget.18467. eCollection 2017 Oct 24. Review.

16.

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.

Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.

17.

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.

Chae YK, Wang S, Nimeiri H, Kalyan A, Giles FJ.

Oncotarget. 2017 Jun 3;8(34):57889-57897. doi: 10.18632/oncotarget.18361. eCollection 2017 Aug 22.

18.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

PMID:
28751450
19.

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ.

Cancer Manag Res. 2017 Jun 14;9:207-213. doi: 10.2147/CMAR.S136818. eCollection 2017. Review.

20.

Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.

Florek AG, Nardone B, Thareja S, Tran G, Giles FJ, West DP.

Br J Dermatol. 2017 Nov;177(5):e220-e221. doi: 10.1111/bjd.15752. Epub 2017 Oct 22. No abstract available.

PMID:
28646575
21.

Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.

Costa R, Costa RB, Talamantes SM, Helenowski I, Peterson J, Kaplan J, Carneiro BA, Giles FJ, Gradishar WJ.

Breast. 2017 Oct;35:1-7. doi: 10.1016/j.breast.2017.05.016. Epub 2017 Jun 12. Review.

PMID:
28618307
22.

Overcoming immunosuppression in bone metastases.

Reinstein ZZ, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA.

Crit Rev Oncol Hematol. 2017 Sep;117:114-127. doi: 10.1016/j.critrevonc.2017.05.004. Epub 2017 May 12. Review.

PMID:
28600175
23.

Wnt/beta-catenin pathway: modulating anticancer immune response.

Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ.

J Hematol Oncol. 2017 May 5;10(1):101. doi: 10.1186/s13045-017-0471-6. Review.

24.

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.

Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M.

Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.

25.

Erratum to: MicroCT-Based Virtual Histology Evaluation of Preclinical Medulloblastoma.

Prajapati SI, Kilcoyne A, Samano AK, Green DP, McCarthy SD, Blackman BA, Brady MM, Zarzabal LA, Tatiparthi AK, Sledz TJ, Duong T, Ohshima-Hosoyama S, Giles FJ, Michalek JE, Rubin BP, Keller C.

Mol Imaging Biol. 2017 Jun;19(3):483. doi: 10.1007/s11307-017-1079-5. No abstract available.

PMID:
28389781
26.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

27.

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ.

Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Review.

PMID:
28279895
28.

Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8-Negative Castleman Disease.

Zhou XA, Chae YK, Giles FJ.

JAMA Dermatol. 2017 May 1;153(5):381-382. doi: 10.1001/jamadermatol.2016.5555. No abstract available.

PMID:
28241212
29.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, Rea D, Castagnetti F, Hellmann A, Rosti G, Gattermann N, Coronel MLP, Gutierrez MAE, Garcia-Gutierrez V, Vincenzi B, Dezzani L, Giles FJ.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.

30.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G.

Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.

31.

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.

PMID:
28177431
32.

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ.

Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1. No abstract available.

33.

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ.

Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5. Review.

PMID:
28104566
34.

Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia.

McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, Giles FJ, Thaxton CS, Ghia P.

Oncotarget. 2017 Feb 14;8(7):11219-11227. doi: 10.18632/oncotarget.14494.

35.

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP.

Clin Cancer Res. 2017 Apr 15;23(8):1891-1897. doi: 10.1158/1078-0432.CCR-15-2240. Epub 2017 Jan 4. Review.

36.

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ.

Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. Review.

37.

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M.

Oncotarget. 2017 Feb 14;8(7):12417-12432. doi: 10.18632/oncotarget.13778. Review.

38.

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.

Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ.

Oncotarget. 2017 Jan 31;8(5):8910-8920. doi: 10.18632/oncotarget.13315. Review.

39.

Genomic characterization of high-risk non-muscle invasive bladder cancer.

Meeks JJ, Carneiro BA, Pai SG, Oberlin DT, Rademaker A, Fedorchak K, Balasubramanian S, Elvin J, Beaubier N, Giles FJ.

Oncotarget. 2016 Nov 15;7(46):75176-75184. doi: 10.18632/oncotarget.12661.

40.

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.

Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ.

Oncotarget. 2016 Oct 4;7(40):65364-65373. doi: 10.18632/oncotarget.11692.

41.

Long-acting interferon for myeloproliferative neoplasms - an update.

Pai SG, Kaplan JB, Giles FJ.

Expert Rev Hematol. 2016 Oct;9(10):915-7. doi: 10.1080/17474086.2016.1231571. Epub 2016 Sep 13. No abstract available.

PMID:
27584865
42.

FGFR3-TACC3 fusion in solid tumors: mini review.

Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ.

Oncotarget. 2016 Aug 23;7(34):55924-55938. doi: 10.18632/oncotarget.10482. Review.

43.

Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.

Kosciuczuk EM, Saleiro D, Kroczynska B, Beauchamp EM, Eckerdt F, Blyth GT, Abedin SM, Giles FJ, Altman JK, Platanias LC.

Blood. 2016 Jul 21;128(3):410-4. doi: 10.1182/blood-2016-02-698704. Epub 2016 Jun 15.

44.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.

PMID:
27137346
45.

Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.

Iqbal A, Eckerdt F, Bell J, Nakano I, Giles FJ, Cheng SY, Lulla RR, Goldman S, Platanias LC.

Oncotarget. 2016 May 31;7(22):33192-201. doi: 10.18632/oncotarget.8899.

46.

The challenge of developmental therapeutics for adrenocortical carcinoma.

Costa R, Carneiro BA, Tavora F, Pai SG, Kaplan JB, Chae YK, Chandra S, Kopp PA, Giles FJ.

Oncotarget. 2016 Jul 19;7(29):46734-46749. doi: 10.18632/oncotarget.8774. Review.

47.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

48.

Is Personalized Medicine Here?

Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ.

Oncology (Williston Park). 2016 Apr;30(4):293-303, 307. Review.

49.

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.

Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM.

PLoS One. 2016 Apr 7;11(4):e0152585. doi: 10.1371/journal.pone.0152585. eCollection 2016.

50.

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ.

Drug Des Devel Ther. 2016 Feb 29;10:873-84. doi: 10.2147/DDDT.S93459. eCollection 2016. Review.

Supplemental Content

Loading ...
Support Center